Aurora Cannabis Inc. (ACB) Stock Price & How to Invest

Aurora Cannabis is a Canadian licensed cannabis producer that has spent the past several years reinventing itself. Once one of the most hyped names of the 2018-2019 cannabis boom, it has since exited low-margin Canadian consumer (recreational) cannabis and non-core operations to concentrate on global medical cannabis, which carries higher and more durable margins. In its fiscal 2026 the company reported record medical results: global medical net revenue grew sharply, international medical revenue rose even faster (led by Germany and Poland), and adjusted EBITDA and free cash flow turned meaningfully positive, a real shift from years of cash burn. International medical, its highest-margin segment, now makes up a majority of medical revenue. To feed that demand, Aurora acquired Safari Flower Company, an EU-GMP certified European cultivator, and in February 2026 it completed the divestiture of its controlling stake in Bevo Agtech, its plant-propagation business, further sharpening the focus on medical cannabis.

The other half of the story is risk. Aurora carries one of the sector's most painful capital-structure histories: repeated equity raises and a cumulative reverse-split history (its share count today reflects roughly a 1-for-120 reduction over time) destroyed enormous per-share value, and the market still discounts the name heavily as a result. Even after the medical turnaround, management has guided fiscal 2027 EBITDA lower, partly because of reduced Canadian medical reimbursement rates taking effect in April 2026, with European growth only partly offsetting that. Cannabis remains a small, fast-changing, heavily regulated industry where policy shifts in any single country can swing results, and Aurora is a small-cap whose shares can move violently on news. That combination is why it is best treated as a speculative position rather than a core holding.

The central risk is Aurora's capital-structure history: repeated equity raises and a cumulative reverse-split history (roughly 1-for-120 over time) have destroyed per-share value, and further dilution would do so again. Even after the medical turnaround, management guided fiscal 2027 EBITDA lower, partly due to reduced Canadian medical reimbursement rates from April 2026, so profitability may not grow smoothly. As a small-cap in a small, fast-changing industry, Aurora is heavily exposed to regulation: a policy change in Germany, Poland, Canada, or any key market can swing results quickly, and the whole sector is prone to sharp sentiment-driven moves. Currency swings between the Canadian dollar, euro, and US dollar affect reported results. Competition from Tilray, Canopy Growth, and local European producers is intense. The shares are volatile and speculative, and the stock has no dividend.

A simple financial snapshot. These are approximations and refresh quarterly; for current figures see Aurora Cannabis Inc.'s investor relations page or your broker.

• Business model: Canadian cannabis producer pivoting to higher-margin global medical cannabis, with EU-GMP supply into Germany, Poland, and other international markets
• Revenue trend: Medical (especially international) growing fast, but total revenue expected to ease toward earlier levels as low-margin Canadian consumer and non-core units are exited; verify latest figures
• Profitability: Record fiscal 2026 medical results; adjusted EBITDA and free cash flow turned positive, a shift from years of losses, though management guides fiscal 2027 EBITDA lower
• Share count: Around 59 million common shares as of early 2026, reflecting a heavy cumulative reverse-split history (roughly 1-for-120 over time)
• Balance sheet: Management emphasizes a cash-rich, relatively low-debt position; confirm current cash and debt in the latest filings
• How it trades: As a speculative, high-volatility small-cap that can move sharply on cannabis-sector and single-country regulatory news; no dividend

These points are qualitative and tied to the asOf date; verify live numbers before acting. For a stock like Aurora, headline revenue growth matters less than whether profitability is durable and whether the company can fund itself without issuing more shares, because dilution has repeatedly overwhelmed operating progress in the past. Be cautious with per-share comparisons across time given the reverse-split history, and always check the current share count, cash position, and latest guidance directly in the filings.

There are three common ways to get ACB exposure. Buy shares (or fractional shares) directly at any major broker. Hold an ETF that includes it, which spreads the position across many companies. Or build it into a focused thematic basket, so ACB sits alongside other stocks that express the same thesis.

Walnut takes the basket route. Describe a thesis where ACB fits (for example “AI infrastructure” or “dividend-growth large-caps”) and the AI proposes 5 to 6 constituents with target weights. You review the plan and fund it through your own broker when you're ready.

Aurora is a speculative small-cap cannabis stock now built around profitable, fast-growing international medical sales, a real improvement over its cash-burning past. But a history of dilution and reverse splits, soft Canadian pricing, and sector-wide regulatory uncertainty keep it high risk. Treat it as a volatile bet, not a stable holding.